Castle Biosciences (NASDAQ:CSTL) Sets New 12-Month Low at $43.13

Castle Biosciences, Inc. (NASDAQ:CSTL) reached a new 52-week low during trading on Tuesday . The stock traded as low as $43.13 and last traded at $43.35, with a volume of 3109 shares. The stock had previously closed at $45.14.

CSTL has been the subject of several recent analyst reports. Robert W. Baird raised their target price on Castle Biosciences from $78.00 to $82.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 9th. Canaccord Genuity raised their target price on Castle Biosciences from $47.00 to $52.00 and gave the stock a “buy” rating in a research note on Friday, September 3rd. Zacks Investment Research cut Castle Biosciences from a “hold” rating to a “sell” rating in a research note on Thursday, November 11th. Finally, SVB Leerink decreased their target price on Castle Biosciences from $85.00 to $75.00 and set an “outperform” rating for the company in a research note on Tuesday, November 9th. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $78.83.

The business’s 50 day moving average is $63.76. The stock has a market capitalization of $1.13 billion, a PE ratio of -36.77 and a beta of 0.47.

Castle Biosciences (NASDAQ:CSTL) last announced its quarterly earnings data on Sunday, November 7th. The company reported ($0.47) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.13). Castle Biosciences had a negative net margin of 34.46% and a negative return on equity of 6.76%. During the same period last year, the firm posted ($0.23) earnings per share. As a group, sell-side analysts predict that Castle Biosciences, Inc. will post -1.42 earnings per share for the current year.

In related news, insider Derek J. Maetzold sold 10,000 shares of Castle Biosciences stock in a transaction on Tuesday, August 31st. The stock was sold at an average price of $75.70, for a total transaction of $757,000.00. Following the sale, the insider now directly owns 355,124 shares in the company, valued at $26,882,886.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Bernhard E. Spiess sold 15,401 shares of the business’s stock in a transaction on Thursday, September 2nd. The shares were sold at an average price of $75.78, for a total value of $1,167,087.78. The disclosure for this sale can be found here. Insiders sold 88,734 shares of company stock worth $6,087,760 in the last 90 days. Corporate insiders own 15.40% of the company’s stock.

A number of large investors have recently modified their holdings of CSTL. First Bank & Trust bought a new position in Castle Biosciences during the second quarter worth about $31,000. Harbor Investment Advisory LLC bought a new position in shares of Castle Biosciences in the third quarter valued at approximately $36,000. First Horizon Advisors Inc. boosted its position in shares of Castle Biosciences by 161.5% in the third quarter. First Horizon Advisors Inc. now owns 999 shares of the company’s stock valued at $57,000 after acquiring an additional 617 shares during the period. UBS Group AG boosted its position in shares of Castle Biosciences by 84.7% in the third quarter. UBS Group AG now owns 1,256 shares of the company’s stock valued at $83,000 after acquiring an additional 576 shares during the period. Finally, Great West Life Assurance Co. Can boosted its position in shares of Castle Biosciences by 36.0% in the first quarter. Great West Life Assurance Co. Can now owns 1,292 shares of the company’s stock valued at $88,000 after acquiring an additional 342 shares during the period. Hedge funds and other institutional investors own 82.84% of the company’s stock.

About Castle Biosciences (NASDAQ:CSTL)

Castle Biosciences, Inc is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma.

Featured Article: How prevalent are 12b-1 fees?

Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.